DelMar Pharmaceuticals Presents Poster at AACR’s Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer Oct 3, 2017 Life Science
RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Oct 3, 2017 Life Science
RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018 Oct 2, 2017 Life Science
DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer Sep 27, 2017 Life Science
CEO Jeffery Bacha Discusses DelMar’s VOL-083 Clinical Trials and the Major Milestones Ahead Sep 26, 2017 Life Science
Ping An Strategically Invests in Tsumura and Becomes Its Largest Shareholder Sep 26, 2017 Life Science
DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market Sep 22, 2017 Life Science
